Assessment of baseline pretreatment factors and on‐treatment virological response to predict sustained virological response in patients with chronic hepatitis C treated with pegylated interferon and ribavirin
Advances in Digestive Medicine · 2017
DOI: 10.1002/aid2.12004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Digestive Medicine, 2017. Verfasst von Shi‐Chi Wen und 6 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pao-Chien hospital, Ping-Tung.
Abstract (Originalsprache)
Backgrounds Pegalated interferon (PEG‐IFN) combination with ribavirin (RBV) (PR) in accordance to response‐guide therapy (RGT) is a treatment option for chronic hepatitis C (CHC) in the past decade. Baseline host and viral factors and early viral kinetics are important determinants for patient using combination therapy.
Aims
We aimed to investigate the effects of host and viral factors on sustained virus response (SVR). We researched the possible predictors of an SVR.
Methods
We retrospectively analyzed a total of 158 CHC patients who had been treated with a PR dual therapy. Clinical parameters and virological responses were analyzed for their relationship with SVR.
Results
The overall SVR rate was 71.5% (113/158). Factors associated with an SVR were ALT levels > 3xULN, non‐AST/ALT > 1, non‐genotype 1 and non‐cirrhosis. Non‐genotype 1 (OR: 3.154; 95% CI: 1.309‐7.601; P = 0.010), and non‐cirrhosis (OR: 2.696; 95% CI: 1.045‐6.956; P = 0.004) were the predictors of an SVR. An SVR significantly increased in patients with an RVR and significantly reduced in patients with cEVR, pEVR, null response and relapse. In addition, an RVR was a powerful independent predictor of an SVR (OR: 38.263; 95% CI: 10.184‐143.757; P = 0.000). The positive predictive value (PPV) of an RVR on SVR was 92.2% (94/102).
Conclusions
Non‐cirrhosis, non‐genotype 1 and achievement of an RVR are independent predictors of SVR. A 4 week RVR is the best predictor of an SVR in CHC patients with a PR dual treatment. An RVR predicts treatment success early. Copyright © 2016, The Gastroenterological Society of Taiwan, The Digestive Endoscopy Society of Taiwan and Taiwan Association for the Study of the Liver.
Förderung
- Pao-Chien hospital, Ping-Tung
Zitieren
APA
Wen, S., Cheng, L., Hsu, J., Lai, H., Shih, P., Tsai, C., & Kuo, W. (2017). Assessment of baseline pretreatment factors and on‐treatment virological response to predict sustained virological response in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. Advances in Digestive Medicine. https://doi.org/10.1002/aid2.12004
Vancouver
Wen S, Cheng L, Hsu J, Lai H, Shih P, Tsai C, et al. Assessment of baseline pretreatment factors and on‐treatment virological response to predict sustained virological response in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. Advances in Digestive Medicine. 2017. doi:10.1002/aid2.12004
BibTeX
@article{Wen2017,
author = {Wen, Shi‐Chi and Cheng, Lung‐Chih and Hsu, Jui‐Hung and Lai, Hsin‐Wen and Shih, Pei‐Chen and Tsai, Chi‐Chang and Kuo, Wu‐Hsien},
title = {Assessment of baseline pretreatment factors and on‐treatment virological response to predict sustained virological response in patients with chronic hepatitis C treated with pegylated interferon and ribavirin},
journal = {Advances in Digestive Medicine},
year = {2017},
doi = {10.1002/aid2.12004}
}
EUVIMED